&w=3840&q=100)
CDSCO lists 17 drugs safe to flush to prevent harm from misuse at home
The Central Drugs Standard Control Organisation (CDSCO) has released a list of 17 medicines—including opioids such as fentanyl, tapentadol and buprenorphine—permitting the general public to flush them down the sink or toilet to prevent harm to people and pets in the home.
The list is part of the central drug regulator's draft guidance document for the safe disposal of unused or expired drugs, aimed at preventing antimicrobial resistance (AMR) and other public health risks.
'There is a small number of medicines that may be especially harmful and, in some cases, fatal with just one dose if they are used by someone other than the person for whom the medicine was prescribed,' the CDSCO stated in a guidance document dated 26 May.
The CDSCO added that the objective of the guidance document is to provide clear and comprehensive instructions, in accordance with the Drugs and Cosmetics Act and other applicable laws, for the safe disposal of expired and unused drugs.
Unscientific disposal of unused or expired medicines is considered one of the primary sources of environmental pollution, with carelessly discarded antibiotics seeping into soil and water bodies and eventually affecting human life.
'In an effort to tackle the unsafe disposal of unused drugs, state governments, in coordination with local bodies, may establish the methodology and facilities for the collection and disposal of unused or expired drugs according to the provisions of the Biomedical Waste Management Rules, 2016,' the document added.
The draft guidance also details methods for the collection, storage, transport and disposal of 11 other types of expired or unused drug dosages and packaging, with separate instructions for manufacturers, wholesalers, retailers, hospitals and other stakeholders.
These include anti-infectives, antineoplastics, radioactive drugs, and medicines in packaging such as ampoules, aerosol canisters and PVC materials, among others.
The draft proposal for the safe disposal of unused and expired medicines comes five years after it was first placed at the 58th meeting of the Drugs Consultative Committee (DCC) of the CDSCO in July 2020. The committee had recommended constituting a sub-committee to examine the issue and prepare the guidance document.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
an hour ago
- Hindustan Times
Talent loss a major threat to addressing global AMR crisis
Antimicrobial resistance (AMR) is turning out to be one of the major health calamities, with two million deaths projected to occur in India alone by 2025 and 10 million globally. While the discovery of penicillin in 1928, revolutionised the field of medicine and saved millions of lives, the industry has witnessed a constant decline in the development of new antibiotics ever since then. The lack of resources and high investments are the widely considered reasons for this gap, but one key aspect that remains largely overlooked is the loss of potent scientific and research talent for more than two decades. In an in-depth research report, Leaving the Lab, AMR Industry Alliance highlights alarming data on this brain drain phenomenon. According to the study, research and development (R&D) workforce is limited with approximately 3,000 AMR researchers currently active in the world, compared to around 46,000 for cancer and 5,000 for HIV/AIDS. Meanwhile, the total number of authors on all AMR publications declined from a high of 3,599 in 1995 to just 1,827 in 2020. Investigators with a focused research interest in AMR too have further declined since the mid-1990s, falling from a peak of 1,300 to less than 700 by 2020. The situation is even more worrisome in the context of India. According to the World Health Organization (WHO), India contributes only 1% to the global antibacterial R&D pipeline, whereas 84% of this research is concentrated in high-income countries, with another 12% in upper-middle-income economies. For a country like India which not only carries one of the world's highest burdens of AMR but also contributes meaningfully to AMR resistance on the global level, the lack of focus on research and innovation severely undermines the efforts to combat this threat. The 2016 UNGA High-Level Meeting on AMR discussed a number of actions, including talent loss to address these challenges globally. However, the industry is still witnessing slow progress on work to contain AMR. This brain drain could further exacerbate the situation if necessary steps aren't taken to tackle the crisis at hand. This current trajectory of AMR research is deeply troubling and stems from a fundamental market failure. Currently most of the private investors and governments prefer directing fund to research in other disease areas, creating a vacuum for companies and SMEs who actively want to amplify work in the field of AMR. And even if some of the biggest players in the market invest in creating new antibiotics, they often don't attract investment. In recent years, AstraZeneca, Novartis, and Johnson & Johnson have all exited or cut back their work on AMR, including closing R&D facilities, selling antimicrobial portfolios, ending AMR development, and letting go of research teams. While SMEs are more agile and innovative in early-stage research and development of antibiotics in comparison to the bigger players, their situation too is marred by lack of funding globally. According to a report by the BEAM Alliance, 54% of the SME members struggle with enough funds to cover even a year's worth of operations and fear bankruptcy. Biopharmaceutical company, Achaogen is a prime example. Even after securing US FDA approval for plazomicin, the company was still forced to declare bankruptcy in April 2019 – after spending nearly a billion dollars and over a decade developing the antibiotic. This phenomenon further exacerbates the broken market for antimicrobials where major pharmaceutical companies are unable to offer long-term careers as they either fear bankruptcy or lack of investments and funding to continue research. On the incentives front, clinicians in antimicrobial and antifungal R&D teams face significant pay gaps when compared to fellowships across all other specialties. In 2022, 44% of infectious disease fellowships went unfilled in the US – more than double the proportion of unfilled fellowships across all specialties. A 2022 Medscape report showed a pay gap of $4,000 between infectious disease doctors and internal medicine doctors across the US, despite the additional years of training and debt required. While India has made commendable strides in public health in the recent years, AMR continues to represent an unprecedented challenge--it can't be resolved by treatment alone. As the most populated country across the globe, India needs to have a strong, sustained investment in scientific human capital to challenge the future risks related to AMR. The government has initiated varied efforts in identifying and filling gaps in knowledge on the development of new antibiotics and alternatives to existing one to combat AMR. For instance, department of biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC's) mission to amplify research in the identification of new bacterial targets; call for proposals under the AMR Interdisciplinary Research (AMRIT) Team Grants, to foster collaborative research in AMR and collaboration with UK-based innovation charity organisation, Nesta, to create a pipeline of innovators who can develop a point–of–care diagnostic test to conserve antibiotics for future generations, are some of the progressive steps in fight against AMR. Additionally, ICMR's flagship initiative Antimicrobial Resistance Surveillance & Research Network (AMRSN) to generate high-quality data on AMR trends across India through 30 tertiary care hospitals and research institutions; funding R&D in areas such as rapid diagnostics, novel antimicrobials with international bodies like WHO, CDC (USA), and the Fleming Fund are other examples of India's efforts. Despite these efforts, challenges do persist in providing the much-needed boost in generating a talented workforce of scientists, researchers and innovators to fight against AMR. One of the major systemic challenges facing loss of scientific talent is due to academia–industry leakages. Despite producing highly skilled microbiologists, pharmacologists, and biotechnologists, LMICs like India struggle to retain researchers in the AMR domain due to inadequate funding, limited career pathways and lack of translational research ecosystems. Additionally, limited interest from the industry to invest in providing hands-on training to the emerging talent further amplifies the challenges. To mitigate these challenges, India Pharma Inc. needs to support adequate funding and pull incentives to support the talent eager to work in the field of AMR. The industry and the government must come together to support antimicrobial stewardship programs while ensuring adequate resources, and robust research infrastructure to retain and nurture talent in the larger ecosystem. Government bodies like BIRAC should further intensify their schemes like Biotechnology Ignition Grant (BIG) or Small Business Innovation Research Initiative (SBIRI) to seed innovation and support long-term product development, and market access in AMR. Given the alacrity of challenge at hand, India must focus towards creating a robust pipeline or sustained funding ecosystem for retaining talent instrumental in pushing new breakthrough in antibiotic discovery. Ensuring that we have a workforce of trained research personnel will be crucial for research funding to go as far as possible and yield the most successful results to tackle AMR. This article is authored by Saransh Chaudhary, president, Global Critical Care, Venus Remedies Ltd and CEO, Venus Medicine Research Centre.
Time of India
14 hours ago
- Time of India
Amdavadi scientist at Yale aims to combat AMR bacteria using viruses
Ahmedabad: Taking a cue from ancient wisdom – an enemy's enemy is a friend — an associate research scientist from Yale University, with his roots in the city, is working on improving the virus-bacteria interaction to use viruses known as bacteriophages to kill bacteria. Tired of too many ads? go ad free now Dr Jyot Antani is part of the team that aims to further the science of targeting specific bacteria that have developed antimicrobial resistance (AMR) due to which the infection they cause cannot be treated with conventional antibiotics. The study, 'Microscopic Phage Adsorption Assay: High-throughput Quantification of Virus Particle Attachment to Host Bacterial Cells,' by Antani, Timothy Ward, Thierry Emonet, and Paul Turner from Yale University, was published recently in the Proceedings of the National Academy of Sciences (PNAS) journal. "Like humans, bacteria can also be infected by viruses. They bind to the receptors on a bacterial host cell and replicate in a process identified as lytic replication, where the host's resources are used to create more phages. This causes the cell to rupture and die," explains Antani. Globally, these mechanisms are being reviewed as a potential way to address AMR bacterial infections through phage therapy. However, one roadblock is understanding this unique interaction at the microscopic level. The traditional method involves mixing bacteria and viruses in a flask and testing the mixture sample at regular intervals to measure the attachment of the phage (virus) on bacteria. It is time-consuming, labour-intensive and provides only an estimation, said researchers. Antani's team from the Yale Quantitative Biology Institute worked on the problem to develop the Microscopic Phage Adsorption (MPA) assay. Tired of too many ads? go ad free now The published work indicates that the method quantifies the interaction between bacteria and phage at individual levels. "Using fluorescent dye, the phages appear as bright spots against the background of bacteria. Using this technique, researchers can record videos of the phages and bacteria in real time, documenting the dynamic movements and individual attachments of phages to bacteria," read the research summary on the Yale University website, Yale Scientific. Antani said that the breakthrough will help researchers understand the impact of different phage types on bacteria and develop strategies to combat bacteria. "If the sample shows a stable fluorescent dot (phage), it means that it got strongly attached to host bacteria. Phages bind to specific molecules (proteins or sugars) that stick out from the bacterial surface, like a ship docking into its assigned spot in the harbour," he said. "We tried many different species of each, including some notorious bacteria known for becoming resistant to antibiotics. Our approach successfully worked for most phages and bacteria that we tested." Antani's journey from Ahmedabad to New Haven has been inspiring. He studied in Gujarati medium until Class 12 before gaining admission to IIT Bombay where he pursued chemical engineering. He received a scholarship for his PhD at Texas A&M University, where he studied the movement of bacteria. "The Covid and post-Covid phases motivated me to explore the interaction between bacteria and viruses, and I got the postdoctoral opportunity at Yale University," he adds. "There are several interesting projects going on in India in this field, too."
India Gazette
20 hours ago
- India Gazette
Uttarakhand: Valley of Flowers opens for tourists on June 1
Dehradun (Uttarakhand) [India], June 1 (ANI): The world-renowned Valley of Flowers in the Chamoli district of Uttarakhand welcomed tourists on Sunday. On its first day, the forest department staff welcomed visitors at the main gate, where 62 tourists had registered so far in June. This valley features over 300 species of Himalayan flowers. The Valley of Flowers, a UNESCO World Heritage Site, is famous for its over 500 plant species. It is open for tourists every year from June to October. The valley is situated in the Garhwal Himalayas, next to Nanda Devi National Park, and is known for its serene, picturesque beauty. The chief minister announced on Saturday that the Uttarakhand government is ready to take a step toward scientific, safe, and environmentally responsible medicine disposal in the state. Chief Minister Pushkar Singh Dhami has started work towards implementing the guidelines issued by the Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare, in the state. A release said this decision is not just an administrative process but a transformative initiative to make Uttarakhand a model state of a 'green health system' across the country. Health Secretary and Commissioner of the FDA, Dr. R. Rajesh Kumar, said that till now, there has been a lack of a clear and consistent system for the disposal of expired and unused medicines.'This challenge becomes more serious in an environmentally sensitive state like Uttarakhand. Now we are moving towards controlling it under a well-planned system,' Kumar said. He informed that in these guidelines, the process has been decided keeping in mind every stage of the life cycle of medicines from production to consumption and then proper disposal. Kumar further said that under the 'Healthy Citizen, Clean Uttarakhand' mission announced by the Chief Minister, this initiative will take the state towards a green and sustainable healthcare model. With this decision, the possibility of establishing the state as a leading state in the field of environmental responsibility and health security at the national and international levels has also become stronger. Only the active participation of all the parties involved in this entire process, policymakers, business organisations and common citizens, can make this mission successful. Uttarakhand is moving towards becoming an example in this direction. Dr. R. Rajesh Kumar informed that as per the plan of the Health Department, 'Drug Take-Back Sites' will be set up in a phased manner in urban, semi-urban and hilly areas of Uttarakhand. Here, common citizens will be able to deposit unused, expired or spoiled medicines lying in their homes. Medicines from these centres will be collected scientifically and disposed of in specially approved processing units. (ANI)
